Avanos Medical (NYSE: AVNS) saw its stock surge 5.09% in pre-market trading on Tuesday following the release of its first-quarter 2025 financial results. The medical device company reported earnings that significantly exceeded analyst expectations, driving investor optimism.
Avanos Medical announced adjusted earnings of $0.26 per share for Q1, surpassing the analyst consensus estimate of $0.18 by an impressive 44.44%. This represents a substantial 36.84% increase from the $0.19 per share reported in the same period last year. The company's quarterly revenue also beat expectations, coming in at $167.50 million, 3.55% above the analyst estimate of $161.75 million and showing a modest 0.84% year-over-year growth.
Other key financial metrics for the quarter included gross profit of $89.8 million, operating income of $10.3 million, and net income of $6.6 million. The company's EBITDA for Q1 stood at $19.9 million. Despite the challenging economic environment, Avanos Medical maintained its full-year 2025 revenue guidance of $665 million to $685 million, signaling confidence in its future performance. The company also provided an outlook for fiscal year 2025 adjusted EPS in the range of $0.75 to $0.95, with GAAP EPS expected between $0.33 and $0.56.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.